NEW YORK, April 11 - IBM has taken an equity stake in LabBook as part of a strategic alliance to combine LabBook's desktop information retrieval, integration, mining, and visualization software with IBM's back-end data management, data integration, and Internet infrastructure software, the companies said Wednesday.
Financial terms of the agreement and the size of the equity stake were not disclosed.
IBM also has a minority equity stake in protein database provider Structural Bioinformatics and a $10 million equity investment in MDS Proteomics.
Under the terms of the agreement, LabBook will optimize its current software tools and develop future tools for IBM’s DB2 database, DiscoveryLink data integration software, and WebSphere application server. IBM will also serve as the preferred supplier for hardware solutions for LabBook’s clients.
While LabBook’s Genomic XML Browser currently queries, manages, and visualizes heterogeneous data types, DiscoveryLink will add to this capability by providing access to multiple data sources, said Anne-Marie Derouault, director of business development and marketing at IBM Life Sciences.
“LabBook provides a front end to the solutions that IBM provides,” said Adel Mikhail, vice president of strategic development at LabBook. “DiscoveryLink and DB2 can now be loaded with our Human Genome Database and be provided as a complete solution to view and mine this information using our BSML [bioinformatics sequence markup language] standard.”
Derouault noted that the partnership is in line with IBM’s commitment to support XML-based standards in the life science IT community.
Mikhail said the LabBook and IBM technologies could be integrated as soon as the second quarter of the year.